Clinical characteristics and survival analysis of cancer of unknown primary

MINTING MA[1], BIN GUO[2], QIULI DUAN[3], PENGQING JIAO[4], JUNFANG BI[5], SUJU WEI[1], JUNYAN WANG[1], FAN ZHANG[1], YU XU[1], PANPAN ZHANG[6], MING HE[2] and JING JIN[7]

[1]Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China;
[2]Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China;
[3]Department of Anorectum Surgical, Traditional Chinese Medicine Hospital of Shijiazhuang City, Shijiazhuang, Hebei 050051, P.R. China; [4]Department of Immunology and Rheumatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China; [5]Department of Combined Traditional Chinese Medicine and West Medicine, Traditional Chinese Medicine Hospital of Shijiazhuang City, Shijiazhuang, Hebei 050051, P.R. China; [6]Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, 100142, P.R. China; [7]Institute of Cancer, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China

Abstract. Cancer of unknown primary (CUP) is a diagnosis that the primary lesion cannot be confirmed by a series of imaging, endoscopic and pathological examinations. The present study aimed to assess the clinical characteristics and survival outcomes of patients with CUP. The present retrospective observational study included patients diagnosed with malignancies confirmed as CUP using histopathology at the Oncology Department of the Fourth Hospital of Hebei Medical University (Shijiazhuang, China) from January 2009 to January 2021. Clinical and pathological data, genetic testing results, treatment modalities and median overall survival (OS) were analyzed. A total of 107 patients were included, with a mean age of 56.59 years. The median follow-up period was 48.8 months. Adenocarcinoma was the most common patho-logical type (38.3%), followed by squamous cell carcinoma (31.8%) and neuroendocrine carcinoma (16.8%). The median OS was 28.4 months, with 1-, 2-, 3- and 4-year OS rates of 68.2, 54.1, 48.4 and 42.3%, respectively. Imaging revealed that 31 patients (29%) had visceral metastases, and these patients had a significantly shorter median OS compared with those without visceral metastases (8.9 vs. 69 months; P=0.001). Patients who received local treatment (n=31; 29%) had significantly longer survival times than those who did not (69 vs. 17.9 months; P=0.009). Of the 107 patients, 101 (94.4%) received systemic treatment. The median OS times for different treatment groups were as follows: Chemotherapy alone, 28.4 months; chemotherapy combined with immune checkpoint inhibitors, anti-angiogenic agents or targeted therapy, not reached; no chemotherapy, 8.0 months; and untreated, 9.4 months, with significant differences observed among the groups (P=0.008). The survival outcomes of patients with CUP varied based on the presence of visceral metastasis and the treatment modalities employed. Systemic treatments, particularly those incorporating targeted therapy, appear to have the potential to improve prognosis.

Introduction

Cancer of unknown primary (CUP) represents a subset of metastatic malignancies. It is characterized by the inability to identify the primary tumor site, despite comprehensive clinical history taking, systematic physical examinations, imaging studies, endoscopic evaluations, immunohistochem-istry (IHC), genetic testing and other diagnostic methods (1,2). According to previous reports, CUP accounts for 2-10% of all newly diagnosed malignancies from certain regions (3,4). With advancements in diagnostic techniques, the incidence of CUP has now decreased to 1-2% (5-7). Nonetheless, the diagnostic process for CUP remains challenging, requiring meticulous efforts to uncover any diagnostic clues and iden-tify the primary lesion. The diagnosis of CUP is often one of exclusion, aimed at minimizing misdiagnosis and avoiding missed diagnoses of tumors with improved prognoses or curative options.

Currently, the treatment of CUP primarily relies on empirical chemotherapy, as targeted therapies tailored to specific molecular characteristics are typically not feasible. Consequently, patients with CUP generally have a poor prog-nosis, with reported median survival times of <12 months (8). Thus, exploring the pathogenesis of CUP and optimizing its

diagnostic and therapeutic strategies are of utmost importance for improving the outcomes of patients with CUP.

Next-generation sequencing (NGS), also known as second-generation sequencing or high-throughput sequencing, is a DNA sequencing technology widely used in the diagnosis and treatment guidance of malignant tumors. NGS testing enables the identification of adverse prognostic factors such as drug resistance and toxicity during cancer treatment (9). In particular, in non-small cell lung cancer, meaningful therapeutic targets, such as EGFR mutations, anaplastic lymphoma kinase (ALK) gene fusions, ROS-1 and C-MET, have been established as the gold standard for selecting targeted therapies, forming the diagnostic cornerstone for precision treatment (10). Certain research suggests that tumors originating from different tissues exhibit distinct gene expression profiles that correspond to their tissue of origin, and analyzing these gene expression profiles may help to identify the tumor type (11). However, there is currently limited data on the genetic testing of CUP. Therefore, the present study aimed to evaluate the clinical characteristics, IHC and genetic mutation status, as well as the survival outcomes of patients with CUP.

Materials and methods

Study design and patients. The present retrospective study included patients with CUP who attended the Oncology Department of the Fourth Hospital of Hebei Medical University (Shijiazhuang, China) between January 2009 and January 2021. Ethical approval was obtained from the Ethics Committee of the Fourth Hospital of Hebei Medical University (approval no. 2024KS052). As the present study was retrospective, it was exempt from requiring informed consent from the patients. To ensure the accuracy of the study results, the correctness of the diagnosis of the included population is very important, which needs rigorous diagnostic screening, and those who did not have a clear pathological diagnosis and had not undergone adequate whole-body imaging, including chest and abdominal CT and cranial imaging examinations to locate the primary lesion, were excluded. The population included in the present study were patients diagnosed with CUP after adequate evaluation under existing examination and laboratory testing techniques according to European Society for Medical Oncology (ESMO) CUP guidelines (12). The specific inclusion criteria were as follows: i) Histopathologically confirmed malignant tumors; ii) previous thorough evaluation by oncologists following the diagnostic criteria outlined in the 2015 ESMO clinical practice guidelines; and iii) complete clinical and pathological data. The exclusion criteria were as follows: i) Age of <18 years; ii) pathological diagnosis of mesenchymal-origin malignant tumors, peritoneal malignant tumors, malignant melanomas, hematological malignancies or benign tumors; and iii) presence of comorbidities involving other malignant tumors or suspected primary tumor sites.

Data collection. The observational indicators for the present study included the clinical and pathological characteristics, treatment regimens and genetic mutation spectrum of CUP, as well as treatment outcomes. Tissues were fixed in formalin and embedded in wax blocks. Paraffin sections (4 μm thick) were deparaffinized and rehydrated, followed by treatment with 0.02 M EDTA buffer (pH 9.0) and EDTA Antigen Retrieval Solution High-Pressure Heat Retrieval (both from Gene Tech Biotechnology Co., Ltd.) for 2.5 min. IHC and H&E staining were then performed according to a previously published protocol (13).

Ki-67 protein expression reflects the proliferative capacity of tumor cells (14,15). Its expression level can be categorized into three groups: Low (<30%; Fig. S1A), medium (30-60%; Fig. S1B) and high expression (≥60%; Fig. S1C). Programmed death-ligand 1 (PD-L1) expression, including tumor proportion score (TPS) or combined positive score (CPS), was evaluated using methods such as immunohistochemistry (IHC) SP263 pharmDx (Roche Tissue Diagnostics) using the OptiView DAB IHC detection kit, strictly following the manufacturer's instructions on a benchmark XT automatic IHC (BenchMark ULTRA; Roche Tissue Diagnostics), or IHC 22C3 pharmDx (Agilent Technologies, Inc.) using the Dako Autostainer Link 48 IHC platform (Agilent Technologies, Inc.) (16). Low expression was defined as TPS or CPS <10% (Fig. S2A); medium expression as TPS or CPS (10-50%) (Fig. S2B); and high expression as TPS or CPS ≥50% (Fig. S2C).

Patient treatment efficacy and survival follow-up were assessed using the inpatient medical records system of the hospital, outpatient visit records and telephone calls. The follow-up cutoff date was in November 2023. Overall survival (OS) was defined as the time from the date of surgery to the date of death or the end of follow-up.

Statistical methods. Statistical analyses were performed using SPSS 23.0 (IBM Corp.). Categorical data are presented as percentages, and descriptive analyses were performed using frequencies and rates. Survival curves were plotted using the Kaplan-Meier method, and differences in survival time were assessed using the log-rank test. P<0.05 was considered to indicate a statistically significant difference.

Results

Demographic and clinical characteristics of patients with CUP. A total of 127 patients with CUP were initially included in the present study; however, the following were excluded: Patients without a clear pathological diagnostic basis (n=3); patients with a confirmed primary lesion post-discharge (n=3); patients with peritoneal cancer (n=4); patients with mesenchymal-origin tumors (n=4); patients with neuroendocrine tumors (n=2); patients with malignant melanoma (n=3); and patients suspected of having a hematological malignancy (n=1). Ultimately, 107 patients were eligible for analysis (Fig. 1).

Among the 107 patients, 71 were male (66.4%). The age at onset ranged from 21-76 years, with a mean age of 56.59 years. The median follow-up period was 48.8 months. The most common sources of pathological specimens were superficial lymph nodes or superficial non-visceral tissues (n=78; 72.9%). Adenocarcinoma was the most prevalent pathological type, accounting for 41 cases (38.3%), followed by squamous cell carcinoma (n=34; 31.8%) and neuroendocrine carcinoma (n=18; 16.8%). PET-CT scans were performed in 63 cases (58.9%) to aid in identifying the primary lesion, and 31 patients (29.0%) were found to have visceral metastases based on imaging

Figure 1. Patient enrollment process.

findings. Baseline characteristics of the patients in the present study are presented in Table I.

Among the 107 patients, 31 (30.0%) received local treatment, whilst 101 (94.4%) received systemic treatment. Specifically, 56 patients (52.3%) underwent chemotherapy alone, and 20 patients (18.7%) received a combination of chemotherapy and immunotherapy, whilst 14 (13.1%) underwent chemotherapy and anti-angiogenic therapy. A total of two patients received a combination of chemotherapy, anti-angiogenic drugs and immune checkpoint inhibitors as first-line treatment, whilst three patients (2.8%) received a combination of chemotherapy and targeted therapy as first-line treatment. Additionally, six patients (5.6%) did not receive any chemotherapy (Table II). Among these patients who did not undergo chemotherapy, two patients with ALK fusion identified by genetic testing received oral crizotinib, 2 patients received anti-angiogenic drugs combined with immune checkpoint inhibitors and 2 patients were treated with multi-target small molecule anti-angiogenic agents, such as regorafenib and apatinib.

Molecular testing. Among all the included patients, 76 (71.0%) underwent Ki-67 testing, with 10 (9.4%) demonstrating low expression, 33 (30.8%) demonstrating medium expression, and 33 (30.8%) demonstrating high expression. PD-L1 testing was performed in 21 patients (19.6%), with 11 (10.2%) showing low expression, 5 (4.7%) showing medium expression, and 5 (4.7%) showing high expression. Besides Ki-67 and PD-L1 testing, 37 patients underwent genetic testing (Table III). A total of four cases (10.8%) showed no mutations. The most frequently observed mutations were in tumor protein P53 (TP53; n=8), human epidermal growth factor receptor 2 (HER-2/ERBB2; n=7) and SWI/SNF Related BAF Chromatin Remodeling Complex (SMARCA/B; n=6). Other mutations observed in >1 patient but <15% of the patients are detailed in Table IV.

Survival analysis. Among the 107 patients, the median OS was 28.4 months, with 1-, 2-, 3- and 4-year OS rates of 68.2, 54.1, 48.4 and 42.3%, respectively. Patients with visceral metastasis had a significantly shorter median OS compared with those without visceral metastasis (8.9 vs. 69 months; P=0.001). According to the stratified analysis of whether local therapy was applied, the median OS of patients with local treatment was 69 months, and that of patients without local treatment was 17.9 months (P=0.009). The survival time of patients given local treatment was significantly longer compared with those without local treatment. Patients were stratified into the following four groups based on first-line

Table I. Baseline characteristics of the patients in the present study (n=107).

Characteristic	n (%)
Sex	
Male	71 (66.4)
Female	36 (33.6)
Age, years	
≤40	10 (9.3)
>40 and ≤65	75 (70.1)
>65	22 (20.6)
Pathological source	
Lymph nodes and superficial non-visceral organs	78 (72.9)
Visceral organs	16 (15.0)
Bone	9 (8.4)
Malignant pleural effusion	4 (3.7)
Pathological type	
Adenocarcinoma	41 (38.3)
Squamous cell carcinoma	34 (31.8)
Neuroendocrine carcinoma	18 (16.8)
Other	14 (13.1)
PET-CT examination	
Yes	63 (58.9)
No	44 (41.1)
Visceral metastasis	
Yes	31 (29.0)
No	76 (71.0)

PET, positron emission tomography.

Table II. Treatment modalities of the patients in the present study (n=107).

Treatment modality	n (%)
Local treatment	
None	76 (71.0)
Radiotherapy	9 (8.4)
Surgery	15 (14.0)
Surgery + radiotherapy	4 (3.8)
Other local treatments	3 (2.8)
Systemic treatment	
None	6 (5.6)
Chemotherapy	56 (52.3)
Chemotherapy + immunotherapy	20 (18.7)
Chemotherapy + anti-angiogenic therapy	14 (13.1)
Chemotherapy + anti-angiogenic therapy + immunotherapy	2 (1.9)
Chemotherapy + targeted therapy	3 (2.8)
No chemotherapy regimen	6 (5.6)

Table III. Molecular diagnostic features of the patients in the present study (n=107).

Molecular diagnostic feature	n (%)
Genetic testing	
Yes	37 (34.6)
No	70 (65.4)
Ki-67 expression, %	
≥60	33 (30.8)
≥30 and <60	33 (30.8)
<30	10 (9.4)
Not tested	31 (29.0)
PD-L1 expression, %	
<10	11 (10.2)
≥10 and <50	5 (4.7)
≥50	5 (4.7)
Not tested	86 (80.4)

PD-L1, programmed cell death 1 ligand 1.

treatment: i) Chemotherapy alone; ii) chemotherapy combined with immune checkpoint inhibitors, anti-angiogenic drugs or targeted therapies; iii) single-agent targeted therapy or surgery without chemotherapy; and iv) untreated. The median OS times for these groups were 28.4 months, not reached, 8 months and 9.4 months, respectively, with significant differences in survival observed among the four groups (P=0.008; Fig. 2).

Discussion

The findings of the present study indicate that the survival outcomes of patients with CUP differ based on the presence of visceral metastasis and the administered treatment modalities. Systemic therapies, particularly those combining chemotherapy with immune checkpoint inhibitors, anti-angiogenic drugs or targeted therapies, show promise in improving prognosis.

Currently, advancements in imaging technologies, improved tissue acquisition methods for pathology and progress in molecular genetic testing have led to a more rigorous diagnostic approach for CUP. In the present study, PET-CT scans were performed on 58.9% and aggressive IHC and genetic testing accounting for one-third of patients to assist in diagnosing the primary lesion, but the diagnosis of

the primary lesion was still not definitive. Furthermore, the present study explored the current methods for the detection of primary lesions and the reduction in the misdiagnosis rate of metastatic CUP lesions. However, despite these advancements, determining the primary site remains challenging. The following factors may contribute to this issue: i) Metastasis to distant sites may cause the primary tumor to regress or disappear, making it difficult to identify, with 20-50% of patients failing to have a primary tumor identified even upon autopsy; ii) current detection methods may be limited by inadequate sampling or by the removal of the primary tumor during the sampling process; iii) certain primary tumors may be small

Figure 2. Survival analysis. Kaplan-Meier curves demonstrating the overall survival: (A) of all the patients with CUP; (B) according to the visceral metastasis status of the patients with CUP; (C) comparing patients with CUP with and without local treatment; and (D) comparing patients with CUP based on the type of first-line treatment. CUP, cancer of unknown primary.

Table IV. Spectrum of gene mutations in the present study (n=37).

Gene mutation	n (%)
TP53	8 (21.6)
HER-2/ERBB2	7 (18.9)
SMARCA/SMARCB	6 (16.2)
RAS	5 (13.5)
BRAF	4 (10.8)
CDK	4 (10.8)
NTRK	2 (5.4)
NF	3 (8.1)
MET	2 (5.4)
JAK2	2 (5.4)
NOTCH1	2 (5.4)
PIK3CIB	2 (5.4)
POLE	2 (5.4)
PTEN	2 (5.4)
RET	2 (5.4)
RB1	2 (5.4)
TNF	2 (5.4)
STK11	2 (5.4)

or slow-growing, rendering them undetectable through current imaging and detection technologies; iv) the primary tumor may have been eradicated by the immune system; and v) metastatic tumor cells may undergo phenotypic changes, causing them to appear distinct from the primary tumor (such as, poorly differentiated, undifferentiated or heterogeneous) (17). This is consistent with the findings of the present study, as nearly 60% of patients underwent PET-CT examination but still failed to have their primary tumor site identified.

Although IHC is frequently used to predict the primary site in CUP, it is not typically considered a treatment guideline due to the inherent ambiguity of pathology reports, which often employ terms such as 'favor' or 'consistent with' rather than providing a definitive diagnosis (18-20). In a cohort of 252 patients with CUP, the Cancer TYPE ID assay successfully predicted the primary site in 98% of cases (11). However, like IHC, the accuracy of these predictions is difficult to ascertain due to the lack of identified anatomical primary sites. Nevertheless, in a subset of 24 patients with CUP with primary sites identified months after diagnosis, the Molecular Cancer Classifier Assay correctly predicted the primary site in 75% of cases, provided that sufficient tissue for analysis was available (13,21). CUP often presents with widespread metastases, most commonly involving lymph nodes, lungs, bones and liver (22). In the present study, most specimens were

obtained from lymph nodes, followed by visceral organs, bone tissue and pleural effusion.

Apart from the primary tumor site, the pathological type of CUP is another critical factor influencing treatment decisions. A previous study indicated that adenocarcinomas, squamous cell carcinomas, neuroendocrine carcinomas and poorly differentiated carcinomas accounted for 60, 5, 2 and 30% of all pathological types, respectively. Another study by Meijer *et al* (23) reported that adenocarcinoma represented ~41% of all CUP cases. In the present study, adenocarcinoma, squamous cell carcinoma and neuroendocrine carcinoma constituted 38.3, 31.8 and 16.8% of the CUP cases, respectively. Given the unknown primary site, applying limited tissue specimens to refine IHC and genetic testing at key diagnostic points is essential for guiding clinical treatment decisions (24).

Regarding genetic testing, the present study identified TP53, HER-2 and SMARCA as the most commonly mutated genes. The TP53 mutation, known for its association with cancer, is observed in carcinomas originating from several tissues, including lung, colorectal and gynecological cancers. Consequently, TP53 detection generally lacks specificity in determining the primary site (25). Other studies have also reported TP53 as the most frequently mutated gene in CUP. Bochtler *et al* (26) reported a TP53 mutation rate of 49.6%, whereas Gerard *et al* (27) reported an even higher positive rate of 87.5%. These discrepancies highlight differences in baseline characteristics between the cohort in the present study and the aforementioned populations, although the underlying cause of this variation requires further analysis. Median survival varied by histological type, with squamous cell carcinoma demonstrating the longest median survival at 25.1 months and poorly differentiated carcinoma the shortest at 3.0 months. Survival rates for each histological type were generally consistent across sex and physical status, with women showing higher survival rates than men for well-differentiated and moderately differentiated adenocarcinomas. Younger patients aged 18-64 years also tended to have longer survival compared with those aged ≥65 years (28).

The present study has several limitations. First, it is a single-center study with a small sample size of only 107 patients; thus, the findings should be validated in larger multi-center cohorts. Second, not all patients underwent genetic testing, leading to certain gene mutations being identified in only one or two patients, indicating the need for a larger sample size. Third, the data from the PD-L1 expression assay and counting criteria are inconsistent and the detection rate is low in the observed population, and there was a variation in IHC protocols used for different individuals from the cohort, so the data may be biased. Finally, the follow-up period was not long enough to capture long-term outcomes. Future research should focus on expanding the sample size, extending the follow-up duration and ensuring comprehensive genetic testing and PD-L1 for all patients to enhance the robustness of the findings.

In conclusion, the results of the present study support the use of NGS in patients with CUP. The findings also demonstrate the feasibility of integrating genomic analysis with diagnostic histopathology and IHC in a community practice setting. Future research should consider combining diagnostic algorithms with genomic analysis to better characterize unknown primary cancers.

Availability of data and materials

The data of genetic testing reports generated in the present study may be found in the figshare database under accession no. 10.6084/m9.figshare.28012967 or at the following URL: https://figshare.com/s/6111ff335415093eb404. All other data generated in the present study may be requested from the corresponding author.

Authors' contributions

MM and BG performed the experiments and participated in data collection. PJ and JB drafted the manuscript. JW and QD performed the statistical analysis and contributed to the study design. SW, YX, FZ and MH participated in data acquisition, analysis or interpretation. PZ and JJ were responsible for tissue management and preparation. MM and BG confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University (approval no. 2024KS052). Informed consent was not required due to the retrospective nature of the study.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Levi F, Te VC, Erler G, Randimbison L and La Vecchia C: Epidemiology of unknown primary tumours. Eur J Cancer 38: 1810-1812, 2002.
2. Lee MS and Sanoff HK: Cancer of unknown primary. BMJ 371: m4050, 2020.
3. Pavlidis N, Briasoulis E, Hainsworth J and Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39: 1990-2005, 2003.
4. Pavlidis N and Fizazi K: Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 69: 271-278, 2009.
5. Brustugun OT and Helland A: Rapid reduction in the incidence of cancer of unknown primary. A population-based study. Acta Oncol 53: 134-137, 2014.
6. Boo YK, Park D, Lim J, Lim HS and Won YJ: Descriptive epidemiology of cancer of unknown primary in South Korea, 1999-2017. Cancer Epidemiol 74: 102000, 2021.

7. Rassy E and Pavlidis N: The currently declining incidence of cancer of unknown primary. Cancer Epidemiol 61: 139-141, 2019.
8. Ren M, Cai X, Jia L, Bai Q, Zhu X, Hu X, Wang Q, Luo Z and Zhou X: Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China. BMC Cancer 23: 1175, 2023.
9. Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, et al: Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0). Cancer Sci 109: 2980-2985, 2018.
10. Thai AA, Solomon BJ, Sequist LV, Gainor JF and Heist RS: Lung cancer. Lancet 398: 535-554, 2021.
11. Erlander MG, Ma XJ, Kesty NC, Bao L, Salunga R and Schnabel CA: Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn 13: 493-503, 2011.
12. Fizazi K, Greco FA, Pavlidis N and Pentheroudakis G; ESMO Guidelines Working Group: Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26 Suppl 5: vi33-vi38, 2011.
13. Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma XJ and Hainsworth JD: Molecular profiling in unknown primary cancer: Accuracy of tissue of origin prediction. Oncologist 15: 500-506, 2010.
14. Li Z, Li F, Pan C, He Z, Pan X, Zhu Q, Wu W and Chen L: Tumor cell proliferation (Ki-67) expression and its prognostic significance in histological subtypes of lung adenocarcinoma. Lung Cancer 154: 69-75, 2021.
15. Sun X and Kaufman PD: Ki-67: More than a proliferation marker. Chromosoma 127: 175-186, 2018.
16. Wei B, Kang J, Kibukawa M, Arreaza G, Maguire M, Chen L, Qiu P, Lang L, Aurora-Garg D, Cristescu R and Levitan D: Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden and clinical utility for predicting response to pembrolizumab. J Mol Diagn 24: 600-608, 2022.
17. Society of Cancer of Multiple and Unknown Primary of China Anti-Cancer Association: China Anti-Cancer Association guideline for diagnosis and treatment of cancer of multiple and unknown primaries (2023 edition). Chin Oncol 33: 403-422, 2023.
18. Greco FA, Lennington WJ, Spigel DR and Hainsworth JD: Molecular profiling diagnosis in unknown primary cancer: Accuracy and ability to complement standard pathology. J Natl Cancer Inst 105: 782-790, 2013.
19. Weiss LM, Chu P, Schroeder BE, Singh V, Zhang Y, Erlander MG and Schnabel CA: Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. J Mol Diagn 15: 263-269, 2013.
20. Morawietz L, Floore A, Stork-Sloots L, Folprecht G, Buettner R, Rieger A, Dietel M and Huebner G: Comparison of histopathological and gene expression-based typing of cancer of unknown primary. Virchows Arch 456: 23-29, 2010.
21. Meiri E, Mueller WC, Rosenwald S, Zepeniuk M, Klinke E, Edmonston TB, Werner M, Lass U, Barshack I, Feinmesser M, et al: A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist 17: 801-812, 2012.
22. Rassy E and Pavlidis N: Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Rev Clin Oncol 17: 541-554, 2020.
23. Meijer L, Verhoeven RHA, de Hingh IHJT, van de Wouw AJ, van Laarhoven HWM, Lemmens VEPP and Loef C: Extensive diagnostic work-up for patients with carcinoma of unknown primary. Clin Exp Metastasis 38: 231-238, 2021.
24. Beauchamp K, Moran B, O'Brien T, Brennan D, Crown J, Sheahan K and Cotter MB: Carcinoma of unknown primary (CUP): An update for histopathologists. Cancer Metastasis Rev 42: 1189-1200, 2023.
25. Joerger AC, Stiewe T and Soussi T: TP53: The unluckiest of genes? Cell Death Differ: Oct 23, 2024 (Epub ahead of print).
26. Bochtler T, Reiling A, Endris V, Hielscher T, Volckmar AL, Neumann O, Kirchner M, Budczies J, Heukamp LC, Leichsenring J, et al: Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. Int J Cancer 146: 3053-3064, 2020.
27. Gerard L, Garcia J, Gauthier A, Lopez J, Durand A, Hervieu V, Lemelin A, Chardon L, Landel V, Gibert B, et al: ctDNA in neuroendocrine carcinoma of gastroenteropancreatic origin or of unknown primary: The CIRCAN-NEC pilot study. Neuroendocrinology 111: 951-964, 2021.
28. Bytnar JA, Lin J, Moncur JT, Shriver CD and Zhu K: Cancers of unknown primary: Survival by histologic type, demographic features, and treatment in the U.S. Military Health System. Cancer Epidemiol 82: 102316, 2023.